Rethinking biomaterials for the advancement of regenerative research & medicine

HealthX20 is a pioneering biotech company transforming the global biomaterials landscape by making research-grade materials more accessible, affordable, and abundant. By addressing critical bottlenecks in the supply of high-quality biomaterials, we empower scientists, clinicians, and innovators to accelerate discovery, improve experimental reproducibility, and translate breakthroughs into real-world medical solutions.

THE POWER OF X20

X20 Thinking questions fundamental assumptions, existing constraints, and business models entirely.

X20 Requires rethinking the entire system: markets, partners, platforms, technologies, and customer behaviours.

X20 Thinking demands nonlinear approaches, such as leapfrogging technologies, business model pivots, or radical cost restructuring.

X20 Thinking accelerates positive global health outcomes.

Why the global biomaterials ecosystem needs a major rethink

The biomaterials manufacturing ecosystem is broken. Life-changing medical treatments rely on biomaterials, but prices are excessive, access is limited, and a handful of global players control the supply. Innovation is stifled, and patients pay the price.

Imagine if you could make the cost of research-grade biomaterials more affordable; research institutes would experience a renaissance of life-saving breakthroughs.

HEALTHX20 SOLUTION

HX20 will disrupt the biomaterials industry by accelerating R&D, streamlining raw material sourcing, and scaling the production of regenerative ingredients like Native collagen and Hydroxyapatite. By providing faster, sustainably sourced, and more affordable raw materials, Healthx20 will unlock access for researchers and manufacturers, turbocharging medical breakthroughs, advancing regenerative health, and ultimately saving lives across both developed and underserved markets.

What Makes Us Different

At HealthX20, innovation is not a buzzword; it’s our blueprint. We operate at the intersection of Precision Science and proprietary HX20 Technology to deliver truly differentiated biomaterials.

Precision: Provenir

We call it Precision Harvesting. A science-led approach to biomaterial development that prioritises:

100% Traceability from source to application

High-purity extractions that preserve native biofunctionality

Selective use of biological components for maximum therapeutic value

Tailored specifications to meet research, pharmaceutical or cosmetic-grade needs

Ethical sourcing and sustainability at every step

Our precision ensures your product is built on a foundation of integrity and performance.

To ensure this, we have a single source partner to ensure 100% control over raw material

HX20 Tech: Pioneering Sustainable Technologies

Our proprietary HX20 Platform is engineered to upcycle animal by-products into advanced, high-performance biomaterials, responsibly and at scale.

Low-energy thermochemical processes

Natural structure preservation for enhanced biocompatibility

Minimal environmental impact

Modular processing is adaptable to different raw materials

Ready for formulation across food, health, medtech, and personal care sectors

HX20 Technology transforms undervalued streams into life-changing materials.

Multiple species, Multiple products

“In regenerative health, only the rich can afford it when it’s the poor that really need it.”

— Anthony Bertini
Founder, HX20

“If we can make biomaterials more accessible and affordable, we unlock a future where healing isn’t a luxury — it’s a right. Because the power to regenerate tissue, repair bones, or restore function shouldn’t belong to a few — it should belong to everyone.”

— Akshat Talwalkar
Chief Scientist, HX20

"A key advancement in biomaterials science lies in increasing accessibility to high-quality materials. By ensuring equitable access to the building blocks of life-saving research, we can foster innovation and enable more efficient clinical translation."

— Maria Taborda
Senior Scientist, HX20

OUR TEAM

  • FOUNDER & CHAIRMAN

    Anthony is the Founder CEO and Chair of Organic Technology Holdings. As an investor and entrepreneur over the past 35 years in new technologies that have the potential to have a global impact, Anthony bought a fledgling technology in 2012 and formed OTH. The technology was originally designed to work with fish waste. Quickly realizing its potential, he surrounded himself with a respected group of scientists and like-minded investors and individuals to improve and apply a series of technology improvement to treat a variety of organic waste raw materials to create valuable and in demand end products throughout the world to be used in the human food and animal feed, nutraceutical, pharmaceutical and medical research and medical device industries.

  • SENIOR RESEARCH SCIENTIST & LEAD, PHD.

    Maria Isabel Taborda Mejia is a Ph.D. in Biotechnology and a Biomedical Engineer with a strong passion for Industrial Biotechnology, technology development, and business innovation within the circular economy. She specializes in the development of sustainable biomaterials, with a focus on natural Hydroxyapatite (HAp) and Chitin derived from animal by-products. Her work bridges scientific research and industrial application, transforming biological waste into high-value products for use in medical, cosmetic, and agricultural industries. Currently, she contributes her expertise at Organic Technology Holdings, where she leads and supports key R&D initiatives. When she’s not in the lab or working on the next breakthrough, you’ll likely find her chasing sunshine on her bike, tackling a bouldering wall, or going for a refreshing run. Adventure and movement are her favorite ways to recharge

  • CHIEF SCIENTIST

    Akshat Talwalkar has a highly accomplished and uniquely diverse techno-commercial profile that includes a PhD in microbiology, 10 publications in reputed scientific journals, six commercially successful patents in grain enzyme production along with extensive on-field commercial experience of new business and market development, technical sales, process development, strategic planning and key account management across Australia and the Asia Pacific region. Akshat's industrial experience includes substantial hands-on involvement with technology start-ups and large manufacturers where he led the conceptualization and development of new technologies, set up enzyme application labs and pilot plants, worked closely with both production managers and operators to successfully scale up scientifically intricate technologies from lab to production levels and worked closely with key stakeholders of large global clients to effectively transfer the developed technologies, offering continual on-site support until they were successfully integrated and established in customers production processes.

  • RESEARCH SCIENTIST, MSc.

    Mary Sravya Kasu is a biotechnology and bioinformatics specialist currently serving as a Research Scientist at Organic Technology Holdings (OTH). Her expertise spans molecular biology, biochemical analysis, and microbial techniques, with an emphasis on experimental design, analytical validation, and process optimization. Mary holds a Master of Biotechnology and Bioinformatics from Deakin University and a Bachelor of Science in Genetics. Her current work involves hypothesis-driven research and lab-to-pilot-scale experiment execution, sample characterization using mass balance and compositional analysis, and protocol development aligned with NATA/ISO and Good Clinical Research Practice standards. She regularly interfaces with multidisciplinary teams to troubleshoot experiments, refine product formulations, and deliver client-focused R&D solutions under time-critical conditions. Her experience includes designing high-throughput lab assays, preparing technical reports for peer-reviewed and commercial use, and supervising cross-functional teams during large-scale production trials. She has contributed to multiple scientific publications, including studies on gene name misannotation and DNA methylation analysis, published in PLOS Computational Biology and Epigenetics.

  • CFO

    Franco Giugni is a finance professional with a chartered accounting background in taxation and extensive hands-on corporate experience across a broad range of industry sectors, focused on implementing aggressive growth strategies. Franco also leads a specialist corporate advisory firm supporting larger SMEs and small-cap ASX-listed companies with mid-market M&A requirements, as well as providing investment banking services under AFSL. Within our business, Franco plays a key role in closely overseeing the Group’s rapidly expanding local and international operations.

  • CHIEF COMMERCIAL OFFICER

    Simon Adriatico is a sales, marketing and brand professional with extensive experience across the APAC region specialising in brand development, cross border commerce and ingredient commodities trading. Having run a handful of brand and marketing agencies focussed in emerging markets, Simon has worked with several of the world’s top companies including LVMH, Volkswagen Group, IOC, Bacardi and Adidas. An early pioneer of cross border e-commerce, Simon has also developed several food & beverage and health & wellness brands in Asia and Australia. Simon is an innovator and strategic thinker with a global network encompassing a diverse range of industry sectors.

PRODUCTS & SERVICES

HX20 Newsletter Coming Soon

Partner With Us